Drug Trial Radar · NCT02285647
An Open-Label, Randomized, Pivotal, Bioequivalence Study of Oral and Intravenous Rolapitant
Last checked: Nov 20, 2026Latest source record: Aug 25, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
138
Actual
Start
Sep 2014
Primary completion
Apr 2015
Study completion May 2015
Sponsor
- Lead sponsor
- Tesaro, Inc.GSK (GSK)
- Sponsor type
- Industry
- First posted
- Nov 7, 2014
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Prevention
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is an open-label, randomized, single-dose, single-center, parallel-group bioequivalence study of orally- and IV-administered rolapitant in healthy male and female subjects.
Conditions
- Chemotherapy-induced Nausea and Vomiting
Interventions
Rolapitant - OralDrug
Oral Treatment A Investigational Product: Rolapitant Dose: 200 mg (4 x 50 mg) Route of Administration: Oral Dosage Form: Capsule Dosing Condition: Fasted (10 hours overnight)
Rolapitant - IVDrug
IV Treatment B Investigational Product: Rolapitant Dose: 185 mg Route of Administration: IV (30 minutes) Dosage Form: 2 mg/mL solution Dosing Condition: Fasted (10 hours overnight)
Primary outcomes
What the sponsor says the trial is designed to measure.
- AUC0-t: area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentrationTime frame: 39-69 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Parexel
Baltimore, Maryland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.